1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Material Name: Fluorouracil Injection

Trade Name: Fluoroblastin; Fluroblastin; Adrucil
Chemical Family: Mixture
Intended Use: Pharmaceutical product used as Antineoplastic

2. HAZARDS IDENTIFICATION

Appearance: Colorless solution
Signal Word: DANGER

Statement of Hazard: May damage fertility or the unborn child. May cause genetic defects.

Additional Hazard Information:

Short Term: May be absorbed through the skin and cause systemic effects. Active ingredient may be harmful if swallowed.
Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on blood and blood forming organs.

Known Clinical Effects: Adverse effects associated with therapeutic use include gastrointestinal disturbances such as nausea, dyspepsia, and vomiting and gastrointestinal irritation. Effects on blood and blood-forming organs have also occurred.

EU Indication of danger: Toxic to reproduction, Category 2  Mutagenic: Category 2

EU Hazard Symbols: T

EU Risk Phrases:
R46 - May cause heritable genetic damage.
R60 - May impair fertility.
R61 - May cause harm to the unborn child.

Australian Hazard Classification (NOHSC):
2. HAZARDS IDENTIFICATION

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium hydroxide</td>
<td>1310-73-2</td>
<td>215-185-5</td>
<td>C;R35</td>
<td>**</td>
</tr>
<tr>
<td>Fluorouracil</td>
<td>51-21-8</td>
<td>200-085-6</td>
<td>Muta. Cat.2;R46, Repr. Cat.2;R60-61, Xn;R22</td>
<td>5</td>
</tr>
</tbody>
</table>

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Carbon monoxide, carbon dioxide, nitrogen oxides and fluorine-containing compounds

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.
MATERIAL SAFETY DATA SHEET

Material Name: Fluorouracil Injection
Revision date: 19-Jul-2012

Fire / Explosion Hazards:

Not flammable.

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions:
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting:
Contain the source of the spill if it is safe to do so. Soak up with inert absorbent material and dispose of as hazardous waste.

Measures for Environmental Protections:
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills:
Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling:
Restrict access to work area. Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). It is recommended that all operations be fully enclosed and no air recirculated. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Storage Conditions:
Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Sodium hydroxide

ACGIH Ceiling Threshold Limit: 2 mg/m³
Australia PEAK 2 mg/m³
Austria OEL - MAKs 2 mg/m³
Bulgaria OEL - TWA 2.0 mg/m³
Czech Republic OEL - TWA 1 mg/m³
Estonia OEL - TWA 1 mg/m³
France OEL - TWA 2 mg/m³
Greece OEL - TWA 2 mg/m³
Hungary OEL - TWA 2 mg/m³
Japan - OELs - Ceilings 2 mg/m³
Latvia OEL - TWA 0.5 mg/m³
OSHA - Final PELS - TWAs: 2 mg/m³
Poland OEL - TWA 0.5 mg/m³
Slovakia OEL - TWA 2 mg/m³
Slovenia OEL - TWA 2 mg/m³
Sweden OEL - TWAs 1 mg/m³

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

FLUOROURACIL INJECTION
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Fluorouracil

Pfizer Occupational Exposure Band (OEB): OEB 5 (control exposure to <1ug/m³)


Engineering Controls: Engineering controls should be used as the primary means to control exposures. Keep airborne contamination levels below the exposure limits listed above in this section. It is recommended that all operations be fully enclosed and no air recirculated.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

- Hands: Impervious, disposable gloves (double suggested) are recommended if skin contact with drug product is possible and for bulk processing operations.
- Eyes: Safety glasses or goggles
- Skin: Impervious disposable protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
- Respiratory protection: If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear an appropriate respirator with a protection factor sufficient to control exposures to the bottom of the OEB range.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solution  
Molecular Formula: Mixture  
Color: Colorless  
Molecular Weight: Mixture

10. STABILITY AND REACTIVITY

Chemical Stability: Stable under normal conditions of use.

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Fluorouracil

- Rat Oral LD 50 230 mg/kg
- Rat Para-periosteal LD 50 245 mg/kg
- Mouse Oral LD 50 115 mg/kg
- Mouse Intravenous LD 50 81 mg/kg

Sodium hydroxide

- Mouse IP LD50 40 mg/kg
11. TOXICOLOGICAL INFORMATION

Irritation / Sensitization: (Study Type, Species, Severity)

Sodium hydroxide
Eye Irritation Rabbit Severe
Skin Irritation Rabbit Severe

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Fluorouracil
5 Week(s) Dog Oral 175 mg/kg LOAEL Bone marrow

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Fluorouracil
Embryo / Fetal Development Mouse Intraperitoneal 10 - 40 mg/kg/day LOAEL Teratogenic
Embryo / Fetal Development Rat Intraperitoneal 12 - 37 mg/kg LOAEL Teratogenic
Embryo / Fetal Development Hamster Intraperitoneal 3 - 9 mg/kg LOAEL Teratogenic, Fetotoxicity
Embryo / Fetal Development Monkey Intramuscular 40 mg/kg NOAEL Not Teratogenic
Reproductive & Fertility-Males Mouse Intraperitoneal 25 - 50 mg/kg LOAEL Fertility

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Fluorouracil
In Vivo Chromosome Aberration Rat Spermatogonia Positive
Sister Chromatid Exchange Human Lymphocytes Positive
Chromosome Aberration Chinese Hamster Ovary (CHO) cells Positive
Sister Chromatid Exchange Chinese Hamster Ovary (CHO) cells Positive
In Vivo Micronucleus Mouse Positive

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

Fluorouracil
IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.
14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger:
Toxic to reproduction, Category 2
Mutagenic: Category 2

EU Risk Phrases:
R46 - May cause heritable genetic damage.
R60 - May impair fertility.
R61 - May cause harm to the unborn child.

OSHA Label:
DANGER
May damage fertility or the unborn child.
May cause genetic defects.

Canada - WHMIS: Classifications

WHMIS hazard class:
D2a very toxic materials

Sodium hydroxide

CERCLA/SARA Hazardous Substances
and their Reportable Quantities: 1000 lb
Inventory - United States TSCA - Sect. 8(b) 454 kg
Australia (AICS): Present
Standard for the Uniform Scheduling
for Drugs and Poisons: Schedule 5
EU EINECS/ELINCS List 215-185-5

Water for injection

Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
REACH - Annex IV - Exemptions from the obligations of Register: Present
EU EINECS/ELINCS List 231-791-2
15. REGULATORY INFORMATION

Fluorouracil

CERCLA/SARA 313 Emission reporting 1.0 %
CERCLA/SARA - Section 302 Extremely Hazardous 500 lb
TPQs 10000 lb
CERCLA/SARA - Section 302 Extremely Hazardous 500 lb
Substances EPCRA RQs
California Proposition 65 developmental toxicity initial date 1/1/89
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4
EU EINECS/ELINCS List 200-085-6

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R22 - Harmful if swallowed.
R46 - May cause heritable genetic damage.
R60 - May impair fertility.
R61 - May cause harm to the unborn child.

Data Sources: Publicly available toxicity information. Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision:
Updated Section 2 - Hazard Identification. Updated Section 5 - Fire Fighting Measures. Updated Section 6 - Accidental Release Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 15 - Regulatory Information.

Prepared by:
Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet